S

Soligenix
D

SNGX

2.88000
USD
-0.40
(-12.06%)
مفتوح الان
حجم التداول
11,502
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
9,401,316
أصول ذات صلة
A
ALT
-0.02000
(-0.57%)
3.49500 USD
B
BLRX
-0.22000
(-6.06%)
3.41000 USD
C
CVM
-0.71800
(-8.86%)
7.38500 USD
C
CYCC
-0.06000
(-0.67%)
8.94000 USD
S
SGMO
-0.03020
(-6.29%)
0.45010 USD
V
VSTM
1.20000
(21.31%)
6.83000 USD
المزيد
الأخبار المقالات

العنوان: Soligenix Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).